164 related articles for article (PubMed ID: 12700945)
1. Immunocytokines: amplification of anti-cancer immunity.
Davis CB; Gillies SD
Cancer Immunol Immunother; 2003 May; 52(5):297-308. PubMed ID: 12700945
[TBL] [Abstract][Full Text] [Related]
2. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
3. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
[TBL] [Abstract][Full Text] [Related]
4. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
Fournier P; Aigner M; Schirrmacher V
Int J Oncol; 2011 Jun; 38(6):1719-29. PubMed ID: 21424118
[TBL] [Abstract][Full Text] [Related]
5. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
6. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer.
Gillies SD; Lan Y; Brunkhorst B; Wong WK; Li Y; Lo KM
Cancer Immunol Immunother; 2002 Oct; 51(8):449-60. PubMed ID: 12202906
[TBL] [Abstract][Full Text] [Related]
7. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
9. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
Front Immunol; 2020; 11():832. PubMed ID: 32457754
[TBL] [Abstract][Full Text] [Related]
10. Cytokine/Antibody Fusion Protein Design and Evaluation.
Fabilane CS; Stephenson AC; Leonard EK; VanDyke D; Spangler JB
Curr Protoc; 2024 May; 4(5):e1061. PubMed ID: 38775006
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
Neri D
Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
[TBL] [Abstract][Full Text] [Related]
12. Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy.
Ren Z; Zhang X; Fu YX
Clin Cancer Res; 2024 May; 30(10):2025-2038. PubMed ID: 38190116
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
14. Immunocytokines for cancer treatment: past, present and future.
Neri D; Sondel PM
Curr Opin Immunol; 2016 Jun; 40():96-102. PubMed ID: 27060634
[TBL] [Abstract][Full Text] [Related]
15. The present and future of immunocytokines for cancer treatment.
Gout DY; Groen LS; van Egmond M
Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
[TBL] [Abstract][Full Text] [Related]
16. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
17. A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.
Winter J; Barbin K; Bacci C; Bunte T
J Pharm Biomed Anal; 2011 Jan; 54(1):81-6. PubMed ID: 20828971
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.
Ziffels B; Pretto F; Neri D
Immunotherapy; 2018 Mar; 10(3):177-188. PubMed ID: 29370721
[TBL] [Abstract][Full Text] [Related]
19. Targeted cytokines for cancer immunotherapy.
Lode HN; Reisfeld RA
Immunol Res; 2000; 21(2-3):279-88. PubMed ID: 10852128
[TBL] [Abstract][Full Text] [Related]
20. Inference of molecular structure for characterization and improvement of clinical grade immunocytokines.
Ongaro T; Guarino SR; Scietti L; Palamini M; Wulhfard S; Neri D; Villa A; Forneris F
J Struct Biol; 2021 Mar; 213(1):107696. PubMed ID: 33493635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
